Form 4: Regeneron Director Acquires Equity and Options

Regeneron Pharmaceuticals Director George L. Sing reported the acquisition of restricted stock units and non-qualified stock options.

Summary

• George L. Sing, a Director of Regeneron Pharmaceuticals, Inc. (REGN), reported an acquisition of equity securities.
• Acquired 155 shares of Common Stock, representing time-based vesting restricted stock units, with an acquisition price of $0.0.
• Acquired 1,962 Non-Qualified Stock Options (right to buy) with an exercise price of $772.76.
• The stock options will become exercisable in portions: a part on the date of the Issuer's first annual meeting of shareholders following the grant date, and the remainder on the first anniversary of the grant date.
• The stock options have an expiration date of January 2, 2036.
• Following these transactions, George L. Sing directly beneficially owns 31,007 shares of Common Stock and 1,962 derivative securities (Non-Qualified Stock Options).
• Indirect beneficial ownership includes 750 shares of Common Stock by spouse, 400 shares by spouse/custodian for son, and 1,000 shares by a trust for son.

Sentiment

Score: 6

Explanation: A director's acquisition of company equity, likely as part of compensation, generally indicates alignment of interests, though it is a routine filing and not indicative of extraordinary events.

Positives

• A director's acquisition of company equity, including restricted stock units and stock options, aligns their interests with those of shareholders, potentially signaling confidence in the company's future performance.

Future Outlook

A portion of the acquired stock options will become exercisable on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder becoming exercisable on the first anniversary of the grant date. The restricted stock units are time-based vesting.

Industry Context

This is a routine insider transaction filing, common across all industries, reflecting a director's compensation or equity participation plan. It does not inherently reflect broader industry trends but is a standard corporate governance disclosure.

Related Party Transactions

• Indirect beneficial ownership of 750 shares of Common Stock by spouse.
• Indirect beneficial ownership of 400 shares of Common Stock by spouse/custodian for son.
• Indirect beneficial ownership of 1,000 shares of Common Stock by a trust for son.

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive sign of management's commitment and alignment with shareholder interests.

Next Steps

• Vesting of the 155 restricted stock units over time.
• Portions of the 1,962 non-qualified stock options becoming exercisable on the date of the Issuer's first annual meeting following grant and on the first anniversary of the grant date.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Equity Acquisition